$Allakos Inc.(ALLK)$ NOT GOOD 🙃The biotech stock plunged so much because the co-primary endpoint misses weren't even close. That's especially problematic because lirentelimab is Allokos' only pipeline candidate in clinical development.
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
3
举报
登录后可参与评论

暂无评论